Biointron, founded in 2012 and ISO 9001:2015 certified, is a Shanghai‑based high‑technology enterprise that specializes in antibody discovery, expression, and optimization. Leveraging fully automated production pipelines, the company offers services such as VHH production, hybridoma sequencing, antibody humanization, affinity maturation, and single B‑cell screening, delivering purified antibodies within two weeks of gene synthesis. With a portfolio that includes recombinant proteins, cytokines, and ADCs, Biointron has supported over 2,000 pharmaceutical clients in more than 20 countries and holds global commercialization reauthorization for its CHO‑K1 cell line. Its commitment to international standards and FDA‑approved DMF filing positions Biointron as a trusted partner for advancing antibody therapeutics from discovery to clinical development.
Biointron is a Contract Research Organization (CRO) specializing in antibody discovery, expression, and optimization services for the biotech and pharmaceutical industries. They are seeking a Bilingual English/Mandarin Business Development Manager to identify business opportunities, build relationships with clients, and assist in the sales process. The role involves market research, client outreach, contract negotiation, and collaboration with cross-functional teams.
Biointron, founded in 2012 and ISO 9001:2015 certified, is a Shanghai‑based high‑technology enterprise that specializes in antibody discovery, expression, and optimization. Leveraging fully automated production pipelines, the company offers services such as VHH production, hybridoma sequencing, antibody humanization, affinity maturation, and single B‑cell screening, delivering purified antibodies within two weeks of gene synthesis. With a portfolio that includes recombinant proteins, cytokines, and ADCs, Biointron has supported over 2,000 pharmaceutical clients in more than 20 countries and holds global commercialization reauthorization for its CHO‑K1 cell line. Its commitment to international standards and FDA‑approved DMF filing positions Biointron as a trusted partner for advancing antibody therapeutics from discovery to clinical development.